Arcus Biosciences Inc

NYSE:RCUSHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG

$18.67−3.56%LiveIn session · ≈ AED 68.57 · Market cap $2.38B · Next earnings Tue 27 Oct

RCUS · Ratios · TradingHolo

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	96.0%	—	—
Operating margin	−159.0%	14.1%	−250.0%	−290.6%	−127.9%	−156.3%	−156.3%	+0.0 pts
Net margin	−157.7%	13.8%	−238.4%	−262.4%	−109.7%	−142.9%	−142.9%	+0.0 pts
EBITDA margin	−153.8%	15.4%	−230.4%	−248.7%	−104.3%	−135.6%	—	—
Return on equity	−24.5%	6.3%	−40.6%	−66.5%	−58.4%	−55.9%	−55.9%	+0.0 pts
Return on assets	−15.9%	3.3%	−19.9%	−28.0%	−24.6%	−31.0%	−31.0%	+0.0 pts
Return on capital employed	−19.1%	3.8%	−24.3%	−37.3%	−35.7%	−42.5%	—	—
Debt / equity	0.0×	0.1×	0.2×	0.0×	0.1×	0.2×	0.2×	+0.0%
Debt / assets	2.3%	7.7%	8.9%	1.0%	5.2%	9.8%	—	—
Interest coverage	0.0×	0.0×	−140.0×	−170.0×	−82.5×	−48.3×	—	—
Current ratio	6.0×	7.6×	5.5×	4.5×	4.5×	4.4×	4.4×	+0.0%
Quick ratio	6.0×	7.6×	5.5×	4.5×	4.5×	4.4×	—	—
Cash ratio	1.4×	0.9×	1.1×	0.7×	0.7×	1.0×	1.0×	+0.0%
Asset turnover	0.1×	0.2×	0.1×	0.1×	0.2×	0.2×	—	—
Receivables turnover	45.9×	0.5×	2.6×	2.8×	10.3×	15.4×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.